NASDAQ:OLMA Olema Pharmaceuticals Q4 2023 Earnings Report $8.28 +0.51 (+6.56%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$8.28 0.00 (0.00%) As of 05:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Olema Pharmaceuticals EPS ResultsActual EPS-$0.49Consensus EPS -$0.49Beat/MissMet ExpectationsOne Year Ago EPSN/AOlema Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOlema Pharmaceuticals Announcement DetailsQuarterQ4 2023Date3/11/2024TimeN/AConference Call DateMonday, March 11, 2024Conference Call Time8:00AM ETUpcoming EarningsOlema Pharmaceuticals' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Olema Pharmaceuticals Earnings HeadlinesHC Wainwright & Co. Reiterates Olema Pharmaceuticals (OLMA) Buy RecommendationOctober 21 at 7:20 PM | msn.comOlema Pharmaceuticals: Tapping The Brakes (Rating Downgrade)October 21 at 7:20 PM | seekingalpha.comI’m sounding the alarmTwo Nobel Prize winners are warning of The Final Displacement — a powerful shift that could spark one of the largest wealth transfers in modern history. According to Goldman Sachs, thousands of Americans are already being financially upended each day while others quietly grow richer. Which side you’re on may depend on what you do next. | Porter & Company (Ad)Olema Shares Sink 28% as Roche Trial Results Weigh on Breast Cancer Drug OutlookOctober 20 at 1:12 PM | msn.comOlema shares drop 28% as Roche trial casts shadow on cancer dataOctober 20 at 8:12 AM | ca.investing.comOlema announces updated data on Phase 1b/2 study of palazestrant, ribociclibOctober 19 at 10:10 PM | msn.comSee More Olema Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Olema Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Olema Pharmaceuticals and other key companies, straight to your email. Email Address About Olema PharmaceuticalsOlema Pharmaceuticals (NASDAQ:OLMA), a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.View Olema Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 Earnings Upcoming Earnings Intel (10/23/2025)Honeywell International (10/23/2025)T-Mobile US (10/23/2025)Lloyds Banking Group (10/23/2025)Vale (10/23/2025)Freeport-McMoRan (10/23/2025)Newmont (10/23/2025)Blackstone (10/23/2025)Digital Realty Trust (10/23/2025)Union Pacific (10/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
